TP3011
TP3011 (CH0793011) is an active metabolite of CH-0793076 and is a potent topoisomerase I inhibitor equipotent as SN38. TP3011 is against cancer cell lines growth with IC50s at the range sub-nanomolar in vitro.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 534605-74-8
- 分子式: C26H26N4O5
- 分子量:474.51
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Topoisomerase アイソフォーム固有の製品をすべて表示
More
生物活性
|
Topoisomerase I |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
0.85 nM
Compound: 6c
|
Antiproliferative activity against human HCT116 cells after 3 days
Antiproliferative activity against human HCT116 cells after 3 days
|
[PMID: 19254843] |
| NCI-H460 | IC50 |
8.2 nM
Compound: 6c
|
Antiproliferative activity against human NCI-H460 cells after 3 days
Antiproliferative activity against human NCI-H460 cells after 3 days
|
[PMID: 19254843] |
| QG-56 | IC50 |
8.5 nM
Compound: 6c
|
Antiproliferative activity against human QG56 cells after 3 days
Antiproliferative activity against human QG56 cells after 3 days
|
[PMID: 19254843] |
TP3011 (0-100 nM; 72 hours) (compound 6c) inhibits cell proliferative activities against various human cancer cell lines, producing 50% inhibition (IC50) of cell growth of 0.85 nM; 8.5 nM; and 8.2 nM in HCT116, QG56, and NCI-H460 (NSCLC) cells, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116, QG56, and NCI-H460 (NSCLC) cells
-
Concentration:0-100 nM
-
Incubation Time:72 hours
-
Result:Was against human cancer cell lines, such as CRC and NSCLC cell lines.
化学情報
-
CAS 番号 534605-74-8
-
分子量 474.51
-
分子式 C26H26N4O5
-
SMILES
O=C(N1CCCCC)NC2=C3C1=C(CN4C(C(COC([C@@]5(CC)O)=O)=C5C=C46)=O)C6=NC3=CC=C2
-
別名
CH0793011
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Anthoney DA, et al. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.BMC Cancer. 2012 Nov 21;12:536. [Content Brief]
[2]. Niizuma S, et al. Synthesis of new camptothecin analogs with improved antitumor activities.Bioorg Med Chem Lett. 2009 Apr 1;19(7):2018-21. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)